Makidono R, Jingu K
Department of Immunology, Kurume University School of Medicine.
Nihon Igaku Hoshasen Gakkai Zasshi. 1991 Jan 25;51(1):44-50.
To determine the predictive value of the IgG anti-cardiolipin antibody test for malignant tumor, two groups of the patients of Kurume and Kyushu University Hospitals were examined by quantitative enzyme linked immunoadsorbent assay (ELISA) for their serum anti-cardiolipin antibodies. With the first group of the patients consisting of a mixture of benign diseases and malignant tumors, the antibody was positive at 57% (39/72). With the second, malignant tumor group, 38% (19/50) was positive for the antibody. When examined for the specificity of the antibodies by a binding inhibition assay, it was shown that the antibodies in the tumor patients were less specific to cardiolipin: antibodies to cardiolipin in tumor patients were blocked by the specific antigen, cardiolipin, in a lesser degree than those in the control syphilis patients, and highly cross-reacted with 2 related phospholipids, i.e., phosphatidyl glycerol and phosphatidic acid. These findings obtained in this study suggest that ELISA for cardiolipin has the value for the tumor diagnosis, supplementing already established assays.
为了确定IgG抗心磷脂抗体检测对恶性肿瘤的预测价值，对久留米大学医院和九州大学医院的两组患者进行了血清抗心磷脂抗体的定量酶联免疫吸附测定（ELISA）。第一组患者包括良性疾病和恶性肿瘤患者，抗体阳性率为57%（39/72）。第二组为恶性肿瘤组，抗体阳性率为38%（19/50）。通过结合抑制试验检测抗体的特异性时发现，肿瘤患者体内的抗体对心磷脂的特异性较低：与对照梅毒患者相比，肿瘤患者体内的抗心磷脂抗体被特异性抗原心磷脂阻断的程度较小，并且与两种相关磷脂即磷脂酰甘油和磷脂酸高度交叉反应。本研究获得的这些结果表明，心磷脂ELISA对肿瘤诊断具有价值，可作为已确立检测方法的补充。
